LFCR
Price
$7.01
Change
+$0.20 (+2.94%)
Updated
Sep 26 closing price
Capitalization
262.64M
4 days until earnings call
NBIX
Price
$142.00
Change
+$1.11 (+0.79%)
Updated
Sep 26 closing price
Capitalization
14.08B
37 days until earnings call
Interact to see
Advertisement

LFCR vs NBIX

Header iconLFCR vs NBIX Comparison
Open Charts LFCR vs NBIXBanner chart's image
Lifecore Biomedical
Price$7.01
Change+$0.20 (+2.94%)
Volume$262.61K
Capitalization262.64M
Neurocrine Biosciences
Price$142.00
Change+$1.11 (+0.79%)
Volume$980.29K
Capitalization14.08B
LFCR vs NBIX Comparison Chart in %
Loading...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LFCR vs. NBIX commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFCR is a StrongBuy and NBIX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (LFCR: $7.01 vs. NBIX: $142.00)
Brand notoriety: LFCR and NBIX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LFCR: 192% vs. NBIX: 108%
Market capitalization -- LFCR: $262.64M vs. NBIX: $14.08B
LFCR [@Pharmaceuticals: Generic] is valued at $262.64M. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.08B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LFCR’s FA Score shows that 1 FA rating(s) are green whileNBIX’s FA Score has 1 green FA rating(s).

  • LFCR’s FA Score: 1 green, 4 red.
  • NBIX’s FA Score: 1 green, 4 red.
According to our system of comparison, NBIX is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LFCR’s TA Score shows that 5 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • LFCR’s TA Score: 5 bullish, 4 bearish.
  • NBIX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than NBIX.

Price Growth

LFCR (@Pharmaceuticals: Generic) experienced а -10.93% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was -2.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

LFCR is expected to report earnings on Oct 02, 2025.

NBIX is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($14.1B) has a higher market cap than LFCR($263M). LFCR has higher P/E ratio than NBIX: LFCR (51.23) vs NBIX (42.01). NBIX YTD gains are higher at: 4.029 vs. LFCR (-5.653). NBIX has higher annual earnings (EBITDA): 557M vs. LFCR (-8.81M). NBIX has more cash in the bank: 976M vs. LFCR (8.27M). LFCR has less debt than NBIX: LFCR (131M) vs NBIX (439M). NBIX has higher revenues than LFCR: NBIX (2.51B) vs LFCR (129M).
LFCRNBIXLFCR / NBIX
Capitalization263M14.1B2%
EBITDA-8.81M557M-2%
Gain YTD-5.6534.029-140%
P/E Ratio51.2342.01122%
Revenue129M2.51B5%
Total Cash8.27M976M1%
Total Debt131M439M30%
FUNDAMENTALS RATINGS
LFCR vs NBIX: Fundamental Ratings
LFCR
NBIX
OUTLOOK RATING
1..100
388
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
10058
PRICE GROWTH RATING
1..100
5846
P/E GROWTH RATING
1..100
627
SEASONALITY SCORE
1..100
5017

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (75) in the Biotechnology industry is in the same range as LFCR (99) in the Industrial Specialties industry. This means that NBIX’s stock grew similarly to LFCR’s over the last 12 months.

NBIX's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that NBIX’s stock grew similarly to LFCR’s over the last 12 months.

NBIX's SMR Rating (58) in the Biotechnology industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that NBIX’s stock grew somewhat faster than LFCR’s over the last 12 months.

NBIX's Price Growth Rating (46) in the Biotechnology industry is in the same range as LFCR (58) in the Industrial Specialties industry. This means that NBIX’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's P/E Growth Rating (6) in the Industrial Specialties industry is in the same range as NBIX (27) in the Biotechnology industry. This means that LFCR’s stock grew similarly to NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LFCRNBIX
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
54%
Momentum
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 14 days ago
58%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
URTY52.621.22
+2.37%
ProShares UltraPro Russell2000
DIVD36.610.29
+0.81%
Altrius Global Dividend ETF
DGP126.490.35
+0.27%
DB Gold Double Long ETN
IHDG45.78-0.02
-0.04%
WisdomTree Intl Hdgd Qual Div Gr ETF
TVE23.63-0.05
-0.21%
Tennessee Valley Authority Power Bonds 1999 Series A due May 1 2029

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and NBIX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and NBIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+2.94%
NBIX - LFCR
32%
Poorly correlated
+0.79%
SHPH - LFCR
31%
Poorly correlated
-3.26%
ALKS - LFCR
30%
Poorly correlated
+2.80%
AMRX - LFCR
29%
Poorly correlated
+1.56%
TKNO - LFCR
25%
Poorly correlated
+4.84%
More

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with ELAN. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+0.79%
ELAN - NBIX
33%
Loosely correlated
+3.65%
LFCR - NBIX
32%
Poorly correlated
+2.94%
CGC - NBIX
31%
Poorly correlated
-2.19%
ALKS - NBIX
31%
Poorly correlated
+2.80%
AQST - NBIX
30%
Poorly correlated
+13.88%
More